CAW
ARRY

Cornerstone Advisors (Washington)’s Array Biopharma Inc ARRY Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-545
Closed -$25K – 1526
2019
Q2 		$25K Sell
545
-1,681
-76% -$47.2K ﹤0.01% 593
2019
Q1 		$54K Buy
2,226
+615
+38% +$12.8K 0.01% 337
2018
Q4 		$23K Buy
1,611
+1,086
+207% +$16.5K ﹤0.01% 483
2018
Q3 		$8K Hold
525
– – 0.01% 701
2018
Q2 		$9K Hold
525
– – 0.01% 633
2018
Q1 		$9K Hold
525
– – 0.01% 624
2017
Q4 		$7K Hold
525
– – ﹤0.01% 654
2017
Q3 		$6K Hold
525
– – ﹤0.01% 687
2017
Q2 		$4K Hold
525
– – ﹤0.01% 739
2017
Q1 		$5K Hold
525
– – ﹤0.01% 708
2016
Q4 		$5K Hold
525
– – ﹤0.01% 721
2016
Q3 		$4K Sell
525
-525
-50% -$2.03K ﹤0.01% 729
2016
Q2 		$4K Hold
1,050
– – ﹤0.01% 632
2016
Q1 		$3K Hold
1,050
– – ﹤0.01% 677
2015
Q4 		$4K Hold
1,050
– – ﹤0.01% 629
2015
Q3 		$5K Buy
+1,050
New +$6.23K ﹤0.01% 563

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Cornerstone Advisors (Washington)'s ARRY Position: Q3 2019 in Review

Cornerstone Advisors (Washington) sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 545 shares — an estimated $25K sold.

Cornerstone Advisors (Washington) first reported a position in ARRY in Q3 2015 and held it in 16 quarters. The position peaked at $54K in Q1 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Cornerstone Advisors (Washington) reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Cornerstone Advisors (Washington) sold 545 Array Biopharma Inc shares in Q3 2019, an estimated $25K.
  • Cornerstone Advisors (Washington) first reported a position in Array Biopharma Inc in Q3 2015 and held it in 16 quarters.
  • Cornerstone Advisors (Washington)'s Array Biopharma Inc position peaked at $54K in Q1 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2019, filed 23 Oct 2019.